GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$74.21
Updated
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.42 |
| 52 Week High | US$87.87 |
| 52 Week Low | US$64.63 |
| Beta | 0.20 |
| 1 Month Change | -10.40% |
| 3 Month Change | -17.73% |
| 1 Year Change | -20.42% |
| 3 Year Change | 3.07% |
| 5 Year Change | -2.55% |
| Change since IPO | 10,237.98% |
Recent News & Updates
Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22
Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Recent updates
Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Gilead Sciences: Realizing Financial Projections Is Key
Mar 20Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77
Mar 13Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
Mar 01Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77
Feb 28We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated
Feb 15Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77
Feb 13Gilead Sciences: Cheap For A Reason
Feb 10Gilead Sciences: The Sky Is Not Falling
Feb 01Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Jan 15What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You
Dec 25These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well
Nov 17Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?
Oct 10We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt
Aug 11Shareholder Returns
| GILD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | -0.2% | 2.9% |
| 1Y | -20.4% | -1.0% | 22.2% |
Return vs Industry: GILD underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: GILD underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 2.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GILD's share price has been volatile over the past 3 months.
Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILD fundamental statistics | |
|---|---|
| Market cap | US$81.58b |
| Earnings (TTM) | US$485.00m |
| Revenue (TTM) | US$27.45b |
168.2x
P/E Ratio3.0x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILD income statement (TTM) | |
|---|---|
| Revenue | US$27.45b |
| Cost of Revenue | US$6.12b |
| Gross Profit | US$21.33b |
| Other Expenses | US$20.84b |
| Earnings | US$485.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 77.70% |
| Net Profit Margin | 1.77% |
| Debt/Equity Ratio | 147.9% |
How did GILD perform over the long term?
See historical performance and comparison